DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Phase 3

Recruiting

Conditions: Juvenile Psoriatic Arthritis

Interventions: Drug: Adalimumab
Drug: Risankizumab

First Posted Date: 2023-10-25

Last Posted Date: 2025-04-25

Lead Sponsor: AbbVie

Target Recruit Count: 40

Registration Number: NCT06100744

Locations: 🇨🇦
British Columbia Children and Women's Hospital and Health Centre /ID# 257884, Vancouver, British Columbia, Canada
🇺🇸
Arkansas Children's Hospital /ID# 258776, Little Rock, Arkansas, United States
🇺🇸
Children's National Medical Center /ID# 259284, Washington, District of Columbia, United States

and more 23 locations

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Phase 3

Withdrawn

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Cisplatin
Drug: Telisotuzumab Vedotin
Drug: Osimertinib
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2023-10-23

Last Posted Date: 2024-06-26

Lead Sponsor: AbbVie

Registration Number: NCT06093503

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma
Pancreatic Ductal Adenocarcinoma
Biliary Tract Cancers
Esophageal Squamous Cell Carcinoma
Triple Negative Breast Cancer
Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Head and Neck Squamous-Cell Carcinoma
Platinum Resistant High Grade Epithelial Ovarian Cancer

Interventions: Drug: ABBV-400

First Posted Date: 2023-10-16

Last Posted Date: 2025-03-10

Lead Sponsor: AbbVie

Target Recruit Count: 260

Registration Number: NCT06084481

Locations: 🇺🇸
City of Hope National Medical Center /ID# 258645, Duarte, California, United States
🇺🇸
University of Colorado Cancer Center - Cancer Clinical Trials Office /ID# 255128, Aurora, Colorado, United States
🇺🇸
Florida Cancer Specialists /ID# 261569, Sarasota, Florida, United States

and more 51 locations

A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers

Phase 1

Not yet recruiting

Conditions: Healthy Volunteers

Interventions: Drug: ABBV-903

First Posted Date: 2023-10-11

Last Posted Date: 2023-10-11

Lead Sponsor: AbbVie

Target Recruit Count: 30

Registration Number: NCT06078202

Locations: 🇺🇸
Acpru /Id# 259438, Grayslake, Illinois, United States

A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants

Phase 1

Withdrawn

Conditions: Healthy Volunteers

Interventions: Drug: Venetoclax

First Posted Date: 2023-10-06

Last Posted Date: 2024-06-21

Lead Sponsor: AbbVie

Registration Number: NCT06070948

Locations: 🇺🇸
Acpru /Id# 259897, Grayslake, Illinois, United States

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: ABBV-787

First Posted Date: 2023-10-05

Last Posted Date: 2025-03-06

Lead Sponsor: AbbVie

Target Recruit Count: 36

Registration Number: NCT06068868

Locations: 🇺🇸
University of Maryland, Baltimore /ID# 253726, Baltimore, Maryland, United States
🇦🇺
Monash Health - Monash Medical Centre /ID# 253841, Clayton, Victoria, Australia
🇺🇸
City of Hope /ID# 253727, Duarte, California, United States

and more 21 locations

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Lutikizumab Dose B
Drug: Lutikizumab Dose A

First Posted Date: 2023-10-05

Last Posted Date: 2024-03-15

Lead Sponsor: AbbVie

Target Recruit Count: 50

Registration Number: NCT06067568

Locations: 🇺🇸
Altasciences Clinical Los Angeles, Inc /ID# 260986, Cypress, California, United States
🇺🇸
Acpru /Id# 259029, Grayslake, Illinois, United States
🇺🇸
PPD Clinical Research Unit - Austin /ID# 260141, Austin, Texas, United States

A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer

Completed

Conditions: Non Small Cell Lung Cancer

First Posted Date: 2023-10-05

Last Posted Date: 2025-01-29

Lead Sponsor: AbbVie

Target Recruit Count: 579

Registration Number: NCT06068842

Locations: 🇦🇪
Burjeel Medical City /ID# 259407, Abu Dhabi, United Arab Emirates
🇧🇷
Hospital Alemao Oswaldo Cruz /ID# 256486, Sao Paulo, Brazil
🇨🇦
Royal University Hospital /ID# 261272, Saskatoon, Saskatchewan, Canada

and more 16 locations

A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants

Phase 3

Active, not recruiting

Conditions: Masseter Muscle Prominence

Interventions: Drug: Placebo
Drug: BOTOX

First Posted Date: 2023-10-05

Last Posted Date: 2024-12-12

Lead Sponsor: AbbVie

Target Recruit Count: 249

Registration Number: NCT06068855

Locations: 🇧🇪
Da Vinci Clinic /ID# 246731, Beerse, Antwerpen, Belgium
🇧🇪
Evolve Clinic /ID# 246729, Schilde, Antwerpen, Belgium
🇧🇪
Universitair Ziekenhuis Brussel /ID# 246311, Jette, Bruxelles-Capitale, Belgium

and more 24 locations

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Phase 3

Recruiting

Conditions: Crohn's Disease

Interventions: Drug: Risankizumab SC
Drug: Placebo for risankizumab

First Posted Date: 2023-10-03

Last Posted Date: 2025-05-22

Lead Sponsor: AbbVie

Target Recruit Count: 276

Registration Number: NCT06063967

Locations: 🇹🇷
Ege University Medical Faculty /ID# 259749, Izmir, Turkey
🇺🇸
Southwest Gastroenterology /ID# 256619, Oak Lawn, Illinois, United States
🇹🇷
Ankara City Hospital /ID# 261906, Ankara, Turkey

and more 168 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy